Autoantibody Response to Murine Double Minute 2 Protein in Immunodiagnosis of Hepatocellular Carcinoma
Figure 3
Autoantibody to MDM2 in serial serum samples from four HCC patients (cases 1, 2, 3, and 4). (a) First HCC patient (case 1) was diagnosed on 02/07/1995 with high titer of anti-MDM2 autoantibody. Totally, we had six serum samples within more than one year of time span collected from this HCC patient. The titer of anti-MDM2 autoantibody became higher at month 9 before HCC was detected. (b) Total of five serum samples were acquired from the second HCC patient (case 2). The titer of anti-MDM2 autoantibody became high at month 6 before the date (11/24/1992) of HCC diagnosed. There was low titer of anti-MDM2 autoantibody before 03/17/1992. (c) The third HCC patient (case 3) was diagnosed at the date of 08/24/1993, with a high titer of anti-MDM2 autoantibody. During one-year period (09/18/1992 to 10/27/1993), six serum samples collected from this patient showed that the titer of anti-MDM2 autoantibody became higher at month 6 before HCC was detected. (d) The fourth HCC patient (case 4) was diagnosed at the date of 01/29/1992, and five serum samples were acquired for test. From 04/17/1991 to 01/29/1992 (the date of detection), a gradually increased titer of anti-MDM2 autoantibody can be seen. It became high at month 6 before HCC was detected. The asterisk means the date of HCC diagnosed.
